HK1211290A1 - Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases - Google Patents

Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases Download PDF

Info

Publication number: HK1211290A1
Authority: HK; Hong Kong
Prior art keywords: heterocycle; methods; substitued; treatment; tetracyclic compounds
Prior art date: 2013-01-16

Application number

HK15112117.6A

Other languages

English (en)

Chinese (zh)

Inventor

Wensheng Yu

Ling Tong

Joseph A. Kozlowski

Oleg Selyutin

Lei Chen

Jae-Hun Kim

Deyou Sha

Razia Rizvi

Bandarpalle Shankar

Bin Hu

Bin Zhong

Dahai Wang

Jinglai Hao

Wei Wei

Tao Ji

Shuai ZAN

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-16

Filing date

2013-12-31

Publication date

2016-05-20

2013-12-31 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2016-05-20 Publication of HK1211290A1 publication Critical patent/HK1211290A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HK15112117.6A 2013-01-16 2013-12-31 Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases HK1211290A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
WOPCT/CN2013/000038		2013-01-16
PCT/CN2013/000038 WO2014110687A1 (en)	2013-01-16	2013-01-16	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
PCT/CN2013/001676 WO2014110705A1 (en)	2013-01-16	2013-12-31	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

Publications (1)

Publication Number	Publication Date
HK1211290A1 true HK1211290A1 (en)	2016-05-20

Family

ID=51208906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15112117.6A HK1211290A1 (en)	2013-01-16	2013-12-31	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

Country Status (26)

Country	Link
US (1)	US9555038B2 (xx)
EP (1)	EP2945952B1 (xx)
JP (3)	JP6093451B2 (xx)
KR (1)	KR101748974B1 (xx)
CN (1)	CN105073755B (xx)
AP (1)	AP2015008625A0 (xx)
AR (1)	AR094496A1 (xx)
AU (1)	AU2013374112B2 (xx)
BR (1)	BR112015016325A2 (xx)
CA (1)	CA2898049C (xx)
CL (1)	CL2015001971A1 (xx)
CR (1)	CR20150378A (xx)
DO (1)	DOP2015000169A (xx)
EA (1)	EA030554B1 (xx)
EC (1)	ECSP15035530A (xx)
HK (1)	HK1211290A1 (xx)
IL (1)	IL239832A0 (xx)
MA (1)	MA38315B1 (xx)
MD (1)	MD20150075A2 (xx)
MX (1)	MX356203B (xx)
PE (1)	PE20151892A1 (xx)
PH (1)	PH12015501560A1 (xx)
SG (1)	SG11201505536RA (xx)
TN (1)	TN2015000293A1 (xx)
TW (1)	TW201441231A (xx)
WO (2)	WO2014110687A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014110687A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
US10457690B2 (en)	2015-06-04	2019-10-29	Merck Sharp & Dohme Corp.	Process for preparing substituted tetracyclic heterocycle compounds
US20180228828A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20180228826A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20190002480A1 (en) *	2015-12-21	2019-01-03	Merck Sharp & Dohme Corp.	Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
WO2017181383A1 (en)	2016-04-21	2017-10-26	Merck Sharp & Dohme Corp.	Hepatitis c virus inhibitors
WO2017219808A1 (zh) *	2016-06-21	2017-12-28	浙江柏拉阿图医药科技有限公司	丙型肝炎病毒抑制剂及应用
WO2018032468A1 (en) *	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018032467A1 (en) *	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
CN109206396B (zh) *	2017-07-05	2023-03-28	上海迪赛诺化学制药有限公司	2-c-甲基-4,5-o-(1-甲基乙烯基)-d-阿拉伯糖酸乙酯的制备方法
CN109232612A (zh) *	2017-07-11	2019-01-18	周龙兴	抑制丙肝病毒的化合物、药物组合物及其用途
US20210361663A1 (en) *	2018-10-26	2021-11-25	Merck Sharp & Dohme Corp.	Formulations of Antiviral Compounds
JP2024525164A (ja) *	2021-06-17	2024-07-10	アテアファーマシューティカルズ，インコーポレイテッド	有利な抗ｈｃｖ併用療法
WO2022266497A1 (en) *	2021-06-17	2022-12-22	Atea Pharmaceuticals, Inc.	Advantageous anti-hcv combination therapy
WO2024259085A2 (en) *	2023-06-14	2024-12-19	Alexion Pharmaceuticals, Inc.	Methods for the synthesis of complement factor d inhibitors and intermediates thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3927630B2 (ja)	1996-09-27	2007-06-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウイルス感染症の予防・治療剤
CN1474815A (zh)	2000-09-20	2004-02-11	Ĭ��ר��ɷ��޹�˾	4-氨基-喹唑啉
WO2005005442A1 (en)	2003-07-10	2005-01-20	Paradigm Therapeutics Ltd.	Silicon compounds and their use
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt)	2004-02-24	2009-06-03	Japan Tobacco Inc	Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
WO2007084413A2 (en)	2004-07-14	2007-07-26	Ptc Therapeutics, Inc.	Methods for treating hepatitis c
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7662809B2 (en)	2004-10-26	2010-02-16	Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa	Tetracyclic indole derivatives as antiviral agents
GB2438802A (en)	2005-02-28	2007-12-05	Univ Rockefeller	Structure of the hepatitis C virus NS5A protein
US7994360B2 (en)	2005-05-16	2011-08-09	Xtl Biopharmaceuticals Ltd.	Benzofuran compounds
US20110104109A1 (en)	2005-07-13	2011-05-05	Frank Bennett	Tetracyclic indole derivatives and their use for treating or preventing viral infections
PL1910338T3 (pl)	2005-07-14	2011-02-28	Irm Llc	Związki heterotetracykliczne jako mimetyki TPO
US7473784B2 (en)	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr)	2005-12-16	2007-06-22	Inst Nat Sante Rech Med	Nouveaux composes interagissant avec pea-15
US7745636B2 (en)	2006-08-11	2010-06-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7642251B2 (en)	2007-08-09	2010-01-05	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US20110130361A1 (en)	2007-08-09	2011-06-02	Jonathan Grimm	Silicon derivatives as histone deacetylase inhibitors
US20090176778A1 (en)	2007-08-10	2009-07-09	Franz Ulrich Schmitz	Certain nitrogen containing bicyclic chemical entities for treating viral infections
AU2008350334B2 (en)	2008-02-13	2013-10-17	Bristol-Myers Squibb Company	Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
PL2310095T3 (pl)	2008-07-22	2013-03-29	Msd Italia Srl	Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
JP5655568B2 (ja)	2008-10-09	2015-01-21	コニカミノルタ株式会社	有機光電変換素子、太陽電池及び光センサアレイ
US8729077B2 (en)	2008-11-28	2014-05-20	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
HK1203929A1 (en)	2008-12-03	2015-11-06	普雷西迪奥制药公司	Inhibitors of hcv ns5a
US8563513B2 (en)	2009-03-27	2013-10-22	Van Andel Research Institute	Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2755658A1 (en)	2009-03-27	2010-09-30	Presidio Pharmaceuticals, Inc.	Fused ring inhibitors of hepatitis c
PL2410844T3 (pl) *	2009-03-27	2016-08-31	Merck Sharp & Dohme	Inhibitory replikacji wirusa zapalenia wątroby typu c
AU2010253790A1 (en)	2009-05-29	2011-12-15	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8221737B2 (en)	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20130156731A1 (en)	2009-12-22	2013-06-20	Kevin X. Chen	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
AR080676A1 (es)	2010-03-09	2012-05-02	Schering Corp	Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
MX2013003634A (es) *	2010-09-29	2013-05-20	Merck Sharp & Dohme	Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2012040923A1 (en) *	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012041014A1 (en) *	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2014110688A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
WO2014110687A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

2013
- 2013-01-16 WO PCT/CN2013/000038 patent/WO2014110687A1/en not_active Ceased
- 2013-12-31 EP EP13871363.1A patent/EP2945952B1/en active Active
- 2013-12-31 MA MA38315A patent/MA38315B1/fr unknown
- 2013-12-31 SG SG11201505536RA patent/SG11201505536RA/en unknown
- 2013-12-31 WO PCT/CN2013/001676 patent/WO2014110705A1/en not_active Ceased
- 2013-12-31 BR BR112015016325A patent/BR112015016325A2/pt not_active Application Discontinuation
- 2013-12-31 MD MDA20150075A patent/MD20150075A2/ro not_active Application Discontinuation
- 2013-12-31 PE PE2015001352A patent/PE20151892A1/es not_active Application Discontinuation
- 2013-12-31 CA CA2898049A patent/CA2898049C/en not_active Expired - Fee Related
- 2013-12-31 EA EA201591328A patent/EA030554B1/ru not_active IP Right Cessation
- 2013-12-31 MX MX2015009225A patent/MX356203B/es active IP Right Grant
- 2013-12-31 AP AP2015008625A patent/AP2015008625A0/xx unknown
- 2013-12-31 KR KR1020157021818A patent/KR101748974B1/ko not_active Expired - Fee Related
- 2013-12-31 US US14/761,256 patent/US9555038B2/en active Active
- 2013-12-31 CN CN201380074735.2A patent/CN105073755B/zh not_active Expired - Fee Related
- 2013-12-31 JP JP2015551946A patent/JP6093451B2/ja not_active Expired - Fee Related
- 2013-12-31 HK HK15112117.6A patent/HK1211290A1/xx unknown
- 2013-12-31 AU AU2013374112A patent/AU2013374112B2/en not_active Ceased
2014
- 2014-01-16 AR ARP140100153A patent/AR094496A1/es unknown
- 2014-01-16 TW TW103101674A patent/TW201441231A/zh unknown
2015
- 2015-06-29 TN TNP2015000293A patent/TN2015000293A1/fr unknown
- 2015-07-08 IL IL239832A patent/IL239832A0/en unknown
- 2015-07-13 CL CL2015001971A patent/CL2015001971A1/es unknown
- 2015-07-13 PH PH12015501560A patent/PH12015501560A1/en unknown
- 2015-07-16 DO DO2015000169A patent/DOP2015000169A/es unknown
- 2015-07-16 CR CR20150378A patent/CR20150378A/es unknown
- 2015-08-17 EC ECIEPI201535530A patent/ECSP15035530A/es unknown
2016
- 2016-11-07 JP JP2016217169A patent/JP6148779B2/ja not_active Expired - Fee Related
- 2016-11-18 JP JP2016225137A patent/JP6417380B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW201441231A (zh)	2014-11-01
KR20150104630A (ko)	2015-09-15
JP6148779B2 (ja)	2017-06-14
BR112015016325A2 (pt)	2017-08-22
PH12015501560A1 (en)	2015-09-21
EP2945952A1 (en)	2015-11-25
MA38315A1 (fr)	2017-02-28
JP6417380B2 (ja)	2018-11-07
ECSP15035530A (es)	2017-08-31
CA2898049C (en)	2018-04-17
PE20151892A1 (es)	2015-12-24
JP2017075158A (ja)	2017-04-20
JP6093451B2 (ja)	2017-03-08
CR20150378A (es)	2015-12-09
WO2014110705A1 (en)	2014-07-24
EP2945952A4 (en)	2016-07-20
EA201591328A1 (ru)	2015-11-30
WO2014110705A9 (en)	2015-03-05
CL2015001971A1 (es)	2015-10-23
US20150335648A1 (en)	2015-11-26
MX356203B (es)	2018-05-18
EP2945952B1 (en)	2019-08-28
DOP2015000169A (es)	2015-12-31
CA2898049A1 (en)	2014-07-24
CN105073755A (zh)	2015-11-18
AU2013374112A1 (en)	2015-07-16
AR094496A1 (es)	2015-08-05
IL239832A0 (en)	2015-08-31
JP2016510321A (ja)	2016-04-07
KR101748974B1 (ko)	2017-06-19
MX2015009225A (es)	2015-10-15
SG11201505536RA (en)	2015-08-28
JP2017095450A (ja)	2017-06-01
WO2014110687A1 (en)	2014-07-24
AU2013374112B2 (en)	2016-11-17
CN105073755B (zh)	2017-08-18
EA030554B1 (ru)	2018-08-31
TN2015000293A1 (en)	2016-10-03
US9555038B2 (en)	2017-01-31
MD20150075A2 (ro)	2016-02-29
MA38315B1 (fr)	2018-05-31
AP2015008625A0 (en)	2015-07-31

Publication	Publication Date	Title
HK1211290A1 (en)	2016-05-20	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2012142093A3 (en)	2013-02-07	2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012125926A3 (en)	2014-05-08	Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
WO2012018534A3 (en)	2013-07-18	Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
NZ703064A (en)	2016-12-23	Inhibitors of hepatitis c virus
NZ631726A (en)	2017-01-27	Therapeutic compounds for the treatment of viral infections
PH12015502443A1 (en)	2016-02-22	6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PH12014500164A1 (en)	2016-10-19	Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
TN2013000421A1 (en)	2015-03-30	2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2013003634A (es)	2013-05-20	Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2020003055A (es)	2020-07-27	Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
TN2012000416A1 (en)	2014-01-30	Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EA201791515A1 (ru)	2017-12-29	Соединения пиразина для лечения инфекционных заболеваний
NZ631754A (en)	2017-02-24	Amide compounds for the treatment of hiv
IN2012DN01855A (xx)	2015-08-21
IN2014MN01547A (xx)	2015-05-08
MX350746B (es)	2017-09-14	Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
MX2012006026A (es)	2012-08-15	Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
MX2014003701A (es)	2015-04-14	Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
WO2013028615A8 (en)	2013-05-23	Novel cyclosporin derivatives for the treatment and prevention of viral infections
UA110849C2 (uk)	2016-02-25	Сполуки для лікування та профілактики респіраторного синцитіального вірусного захворювання